Safety and Efficacy of 99mTc-hydrazinonicotinamide-PEG4-E[PEG4-c(RGDfk)]2 (99mTc-3PRGD2) for Integrin αVβ3 SPECT/CT Imaging of Lung Cancer and Mapping Lymph Node Metastases: A Prospective Multicenter, Self-controlled, Phase 3 Trial
Latest Information Update: 19 Jun 2024
At a glance
- Drugs Technetium 99 niacinamide polyethylene glycol bicyclic RGD peptide RDO Pharm (Primary)
- Indications Lung cancer
- Focus Diagnostic use; Registrational
- Acronyms TRIIL
- Sponsors RDO Pharm
Most Recent Events
- 25 Apr 2022 Status changed from recruiting to completed.
- 23 Jan 2020 New trial record